ALNY vs ARGX
Alnylam Pharmaceuticals, Inc. and argenx SE, both Healthcare
argenx SE is the larger company at $56B against $39B. On trailing earnings ARGX is the cheaper of the two at a P/E of 42.2 against 118.1, a gap that is only a bargain if the two are growing at similar rates. Over the past year ARGX returned +12% against -49% for ALNY. The RyuScore puts ALNY ahead, 15 against 11 out of 100.
| Figure | ALNY | ARGX |
|---|---|---|
| Last close | $233 | $825 |
| Market cap | $39B | $56B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 118.1 | 42.2 |
| 1-year return | -49% | +12% |
| 5-year return | +24% | +156% |
| RyuScoresector-relative, 1–10 | 15/100 | 11/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Alnylam Pharmaceuticals, Inc.
Revenue of $2.5B in H1 2026, net income $370M. Its largest reported line is Amvuttra, 67% of the disclosed total.
argenx SE
Revenue of $2.5B in H2 2025, net income $877M.
Open these two in the interactive comparison to add more names, change the period or see the correlation.